Top entities: Embecta, Hagens Berman, Reed Kathrein, United States — United States Securities and Exchange Commission.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Embecta reduced guidance · Hagens Berman filed class action Embecta · Embecta issued misleading statements

Is this event still developing?

This is an active story, last updated Jul 15, 2026. Coverage continues to evolve.

Regulatory class action

Embecta Securities Class Action Lawsuit

Q: When did this event occur?

First reported Jul 09, 2026; last updated Jul 15, 2026.

Q: What is the market impact?

General. The lawsuit and earnings miss have severely damaged investor confidence in Embecta, leading to a significant stock price decline.

Analysis based on 7 articles · First reported Jul 09, 2026 · Last updated Jul 15, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The lawsuit and earnings miss have severely damaged investor confidence in Embecta, leading to a significant stock price decline. The company's credibility is questioned, and the reduced dividend and guidance indicate ongoing challenges in its core pen needle market.

Medical Devices

Event Summary

Embecta Corp. faces a securities class action lawsuit filed by Hagens Berman on behalf of investors who purchased Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that Embecta made misleading assurances about the stability and resilience of its pen needle business, which formed the basis for its February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80-$3.00. On May 5, 2026, Embecta reported Q2 2026 adjusted EPS of $0.27, a 61% decline, slashed its 2026 EPS guidance to $1.55-$1.75, and reduced its dividend by 93%. The stock price tumbled. The lead plaintiff deadline is August 17, 2026.

Key Actions

100 Embecta reduced guidance

80 Hagens Berman filed class action Embecta

70 Embecta issued misleading statements

Entities Involved

stock

Embecta

Embecta is the defendant in the class action lawsuit; its stock price fell sharply after reporting disappointing Q2 earnings and slashing guidance and dividend.

Importance 100.0 Sentiment -80.0

priv

Hagens Berman

Hagens Berman is the law firm representing investors in the class action lawsuit against Embecta.

Importance 60.0 Sentiment 0.0

per

Reed Kathrein

Reed Kathrein is the Hagens Berman partner leading the investigation into Embecta's alleged securities law violations.

Importance 30.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The SEC's whistleblower program is mentioned as a potential avenue for individuals with non-public information about Embecta.

Importance 20.0 Sentiment 0.0

Relationships

Hagens Berman related ↔ Reed Kathrein

Hagens Berman related ↔ United States — United States Securities and Exchange Commission

Reed Kathrein related ↔ United States — United States Securities and Exchange Commission

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard